Tags

Type your tag names separated by a space and hit enter

Elevated circulating CD40L concentrations in patients with systemic sclerosis.
J Rheumatol. 2004 Mar; 31(3):514-9.JR

Abstract

OBJECTIVE

B cell activation, fibrosis, and expression of adhesion molecules on endothelial cells are regulated by soluble CD40L (sCD40L)/CD40 interactions. Since these effects are characteristic in patients with systemic sclerosis (SSc), serum concentrations of sCD40L were determined in patients with SSc.

METHODS

Fifty-two Japanese patients with SSc were examined. They were grouped into 24 patients with limited cutaneous SSc (lSSc) and 28 with diffuse cutaneous SSc (dSSc). Serum sCD40L levels were examined by ELISA. As a disease control, serum samples from 20 patients with systemic lupus erythematosus (SLE) were also examined. In addition, a retrospective longitudinal study was performed in 71 serum samples from 18 patients with SSc.

RESULTS

Serum sCD40L levels were elevated in SSc patients compared with healthy controls (p < 0.001). Levels of sCD40L in patients with SSc were higher than in patients with SLE (p < 0.001) that had elevated sCD40L levels compared with healthy controls. Among SSc subsets, there were no differences in sCD40L levels between lSSc and dSSc. sCD40L levels correlated positively with C-reactive protein levels in SSc patients (p < 0.0001, r = 0.449). In a cross-sectional study and a longitudinal study, serum sCD40L levels in dSSc patients were persistently elevated, although those in lSSc patients were temporarily elevated at the early phase of the disease process.

CONCLUSION

Patients with SSc exhibited elevated sCD40L levels that may correlate with disease activity. These results suggest that CD40/CD40L interactions may be potential therapeutic targets in SSc.

Authors+Show Affiliations

Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

14994397

Citation

Komura, Kazuhiro, et al. "Elevated Circulating CD40L Concentrations in Patients With Systemic Sclerosis." The Journal of Rheumatology, vol. 31, no. 3, 2004, pp. 514-9.
Komura K, Sato S, Hasegawa M, et al. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol. 2004;31(3):514-9.
Komura, K., Sato, S., Hasegawa, M., Fujimoto, M., & Takehara, K. (2004). Elevated circulating CD40L concentrations in patients with systemic sclerosis. The Journal of Rheumatology, 31(3), 514-9.
Komura K, et al. Elevated Circulating CD40L Concentrations in Patients With Systemic Sclerosis. J Rheumatol. 2004;31(3):514-9. PubMed PMID: 14994397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated circulating CD40L concentrations in patients with systemic sclerosis. AU - Komura,Kazuhiro, AU - Sato,Shinichi, AU - Hasegawa,Minoru, AU - Fujimoto,Manabu, AU - Takehara,Kazuhiko, PY - 2004/3/3/pubmed PY - 2004/6/25/medline PY - 2004/3/3/entrez SP - 514 EP - 9 JF - The Journal of rheumatology JO - J Rheumatol VL - 31 IS - 3 N2 - OBJECTIVE: B cell activation, fibrosis, and expression of adhesion molecules on endothelial cells are regulated by soluble CD40L (sCD40L)/CD40 interactions. Since these effects are characteristic in patients with systemic sclerosis (SSc), serum concentrations of sCD40L were determined in patients with SSc. METHODS: Fifty-two Japanese patients with SSc were examined. They were grouped into 24 patients with limited cutaneous SSc (lSSc) and 28 with diffuse cutaneous SSc (dSSc). Serum sCD40L levels were examined by ELISA. As a disease control, serum samples from 20 patients with systemic lupus erythematosus (SLE) were also examined. In addition, a retrospective longitudinal study was performed in 71 serum samples from 18 patients with SSc. RESULTS: Serum sCD40L levels were elevated in SSc patients compared with healthy controls (p < 0.001). Levels of sCD40L in patients with SSc were higher than in patients with SLE (p < 0.001) that had elevated sCD40L levels compared with healthy controls. Among SSc subsets, there were no differences in sCD40L levels between lSSc and dSSc. sCD40L levels correlated positively with C-reactive protein levels in SSc patients (p < 0.0001, r = 0.449). In a cross-sectional study and a longitudinal study, serum sCD40L levels in dSSc patients were persistently elevated, although those in lSSc patients were temporarily elevated at the early phase of the disease process. CONCLUSION: Patients with SSc exhibited elevated sCD40L levels that may correlate with disease activity. These results suggest that CD40/CD40L interactions may be potential therapeutic targets in SSc. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/14994397/Elevated_circulating_CD40L_concentrations_in_patients_with_systemic_sclerosis_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&amp;pmid=14994397 DB - PRIME DP - Unbound Medicine ER -